Valuation: Protalix BioTherapeutics, Inc.

Market Cap 222M 198M 185M 168M 317M 21.41B 321M 2.23B 865M 10.9B 835M 817M 35.02B P/E 2026 *
11.5x
P/E 2027 * 55.2x
Enterprise Value 222M 198M 185M 168M 317M 21.41B 321M 2.23B 865M 10.9B 835M 817M 35.02B EV / Sales 2026 *
2.71x
EV / Sales 2027 * 3.35x
Free-Float
96.12%
Yield 2026 *
-
Yield 2027 * -
1 day-2.90%
1 week-2.55%
Current month-2.90%
1 month+3.47%
3 months+16.52%
6 months+22.37%
Current year+48.89%
1 week 2.6
Extreme 2.6
2.82
1 month 2.57
Extreme 2.57
2.85
Current year 1.72
Extreme 1.72
3.19
1 year 1.6
Extreme 1.6
3.19
3 years 0.82
Extreme 0.8214
3.19
5 years 0.7
Extreme 0.7
3.55
10 years 0.7
Extreme 0.7
15.15
Manager TitleAgeSince
Chief Executive Officer 59 30/06/2019
Director of Finance/CFO 57 24/08/2025
Chief Tech/Sci/R&D Officer - 01/06/2024
Director TitleAgeSince
Director/Board Member 73 01/07/2008
Director/Board Member 83 01/11/2014
Director/Board Member 59 30/06/2019
Date Insider Type Main position Quantity % Market Cap. Importance
03/09/26 Free

Director

25,500 0.0316%
03/09/26 Free

Chairman

25,500 0.0316%
03/09/26 Free

Chief Executive Officer

480,000 0.5957%
Change 5-day change 1-year change 3-year change Capi.($)
-2.90%-2.55%+13.56%+71.79% 222M
-0.62%-2.71%+39.30%+113.61% 1,031B
-2.30%-4.44%+39.03%+66.72% 638B
-0.63%-1.96%+6.36%+75.33% 462B
-1.03%-2.82%+59.56%+40.23% 359B
-0.03%-3.91%+34.28%+39.35% 335B
-1.58%+0.39%+17.92%+25.77% 273B
-2.02%-3.20%+7.60%+8.38% 253B
-3.38%+0.30%+36.44%+52.93% 228B
-1.04%-1.46%+32.70%+99.06% 185B
Average -1.38%-0.86%+28.68%+59.32% 376.41B
Weighted average by Cap. -1.02%-0.35%+32.51%+69.53%

Financials

2026 *2027 *
Net sales 82.16M 72.97M 68.24M 62.19M 117M 7.91B 119M 826M 320M 4.03B 308M 302M 12.94B 66.48M 59.05M 55.22M 50.32M 94.73M 6.4B 96.04M 668M 259M 3.26B 250M 244M 10.47B
Net income 19.63M 17.44M 16.31M 14.86M 27.98M 1.89B 28.36M 197M 76.37M 963M 73.71M 72.11M 3.09B 3.79M 3.37M 3.15M 2.87M 5.41M 365M 5.48M 38.12M 14.76M 186M 14.24M 13.94M 598M
Net Debt - -
Logo Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Employees
226
Date Price Change Volume
02/10/26 $2.680 -2.90% 1,589,261
30/09/26 $2.760 +2.60% 836,259
29/09/26 $2.690 0.00% 898,556
28/09/26 $2.690 -1.10% 832,815
25/09/26 $2.720 -1.09% 386,025
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.760USD
Average target price
11.00USD
Spread / Average Target
+298.55%

Quarterly revenue - Rate of surprise